SpectraWAVE has announced a US$50M series B funding round which the company says will advance commercial expansion and product additions to its HyperVue imaging system.
The latest round is led by Johnson & Johnson Innovation, joined by S3 Ventures, Lumira Ventures, SV Health Investors, Deerfield Management, NovaVenture, Heartwork Capital, and undisclosed parties.
“Intravascular imaging guidance is backed by a wealth of randomised clinical trials (RCT) and recently collated in a meta-analysis of 22 RCT studies and approximately 16,000 patients published this year in The Lancet, demonstrating significantly improved outcomes for patients undergoing coronary stenting,” said Eman Namati, chief executive officer of SpectraWAVE. “This evidence and broad recognition of impact has recently moved intravascular imaging to a 1A guideline recommendation in Europe, with an expectation that the USA will follow in due time.
“Increasing both the capabilities and the ease of use of intravascular imaging systems is now critical to expand the use of imaging and improve care for these patients. That is our mission with HyperVue—simpler, faster, and better imaging to drive optimised stenting procedures for improved patient outcomes. The reception to the product during our initial US launch has been fantastic, and this financing, supported by leading MedTech investors, will support our commercial expansion to bring HyperVue to more patients.”
Intravascular imaging is a tool to optimise coronary stenting procedures, providing insights into plaque morphology, plaque modification decisions, stent and balloon sizing and landing zone selection, confirmation of treatment optimisation, and future adverse event risk.
HyperVue combines two imaging technologies, DeepOCT and near-infrared spectroscopy (NIRS), while optimising for image quality and procedural efficiency in the cath lab, including no-flush catheter prep, fast and long pullbacks designed to reduce and remove the use of contrast, and the most comprehensive AI-driven workflow and image analysis offering.
Namati added: “In addition to our commercial intravascular imaging system, we are developing a wire-free physiology software add-on to allow physicians rapid assessment of pressure drops in the coronaries using the same HyperVue hardware. This is an important step in our journey to enhance the clinical decision-making for these patients and establish an anchor point for future innovation in the cath lab.”
